Floatz logo

Tucidinostat

Refractory

Ruijin HospitalSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Refractory cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
UNC Lineberger Comprehensive Cancer Center
Phase 2B
Cyclophosphamide
The Second Hospital of Shandong University
Phase 2B
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Isatuximab
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC

View all 33 →

Same molecule, other indications

Tucidinostat is also rated in:

extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →